Skip to main content
← All trials
Advanced Solid TumorsGeneticsCancerDrugPhase 1, Phase 2

What this study is

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

What's being tested

  • Daraxonrasib

    Intervention · DRUG

  • Elironrasib

    Intervention · DRUG

  • Zoldonrasib

    Intervention · DRUG

  • Ivonescimab

    Intervention · DRUG

  • Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)

    Intervention · DRUG

  • cetuximab (Cohort C2 Only)

    Intervention · DRUG

  • Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)

    Intervention · DRUG

  • Daraxonrasib (Cohort B1 only)

    Intervention · DRUG

All of Daraxonrasib, Elironrasib, Zoldonrasib, Daraxonrasib (Cohort B1 only)

oral tablets

All of Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only), cetuximab (Cohort C2 Only), Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)

IV infusion

Study details

Official title
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors
Sponsor
Revolution Medicines, Inc.
Conditions
Advanced Solid Tumors · Metastatic Solid Tumors · Non-small Cell Lung Cancer (NSCLC) · NSCLC · Colorectal Cancer (CRC) · CRC
Enrolling
370 people
Starts
2026-01-30
Est. completion
2029-05
Design
Open-label, non-randomized, parallel groups, Phase 1, Phase 2
Record
View on ClinicalTrials.gov ↗